Published in Clin Cancer Res on February 06, 2013
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int (2014) 1.15
LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis (2015) 1.04
Clinical trials in hepatocellular carcinoma: an update. Liver Cancer (2013) 0.99
DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol (2014) 0.99
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Hepatocellular carcinoma: Where there is unmet need. Mol Oncol (2015) 0.93
HSF1 critically attunes proteotoxic stress sensing by mTORC1 to combat stress and promote growth. Nat Cell Biol (2016) 0.92
Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy. Oncoscience (2013) 0.92
Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget (2014) 0.91
Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. J Hepatol (2014) 0.90
Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget (2013) 0.89
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs (2015) 0.88
Vaspin regulates the osteogenic differentiation of MC3T3-E1 through the PI3K-Akt/miR-34c loop. Sci Rep (2016) 0.87
Targeting hypoxic response for cancer therapy. Oncotarget (2016) 0.85
A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLoS One (2013) 0.85
Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition. Radiology (2015) 0.85
Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol (2015) 0.84
Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene (2015) 0.83
Predicting resistance by selection of signaling pathways. Transl Lung Cancer Res (2014) 0.82
Dynamic expression patterns of differential proteins during early invasion of hepatocellular carcinoma. PLoS One (2014) 0.82
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget (2015) 0.82
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers (Basel) (2014) 0.82
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol (2015) 0.81
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol (2014) 0.80
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol (2017) 0.79
Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One (2015) 0.78
Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma. PLoS One (2015) 0.78
Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2. Oncotarget (2016) 0.77
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs (2014) 0.77
Ablation of Dicer leads to widespread perturbation of signaling pathways. Biochem Biophys Res Commun (2015) 0.76
Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res (2013) 0.76
Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg (2015) 0.76
Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice. Mech Ageing Dev (2016) 0.75
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma. Onco Targets Ther (2017) 0.75
A critical question for cancer therapy: what new targets exist? Transl Lung Cancer Res (2014) 0.75
Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy. J Control Release (2015) 0.75
Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma (2017) 0.75
Damnacanthal, a noni anthraquinone, inhibits c-Met and is a potent antitumor compound against Hep G2 human hepatocellular carcinoma cells. Sci Rep (2015) 0.75
Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma. BBA Clin (2015) 0.75
Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics (2016) 0.75
Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther (2015) 0.75
LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. Cell Death Dis (2016) 0.75
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol (2017) 0.75
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75
Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression. Oncotarget (2015) 0.75
MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk6. Hepatology (2017) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Molecular cloning and expression of human hepatocyte growth factor. Nature (1989) 6.91
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
Targeting MET in cancer: rationale and progress. Nat Rev Cancer (2012) 6.43
Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 6.26
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature (1995) 6.13
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun (1984) 3.70
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 3.53
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39
Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A (1993) 2.86
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol (2001) 2.72
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther (2010) 2.18
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res (2011) 1.92
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci U S A (1998) 1.76
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74
Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol Cell Biol (1993) 1.64
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology (2011) 1.61
Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci U S A (1992) 1.48
Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ (1996) 1.36
Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell (2009) 1.28
Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression. Hepatology (1994) 1.28
Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology (1994) 1.21
Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene (1994) 1.21
Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog (2003) 1.19
Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology (1997) 1.18
Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16
Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett (1991) 1.16
Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther (2005) 1.15
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer (2009) 1.14
Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology (1997) 1.14
u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer (2000) 1.12
c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology (1994) 1.11
In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol (2007) 1.11
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol (2012) 1.08
Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology (1995) 1.08
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene (2002) 1.06
Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem (2004) 0.98
Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. J Hepatol (1996) 0.97
Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci U S A (1996) 0.94
Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis (2011) 0.93
Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology (1996) 0.91
Prognostic impact of surgical complications and preoperative serum hepatocyte growth factor in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg (2008) 0.90
Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res (2009) 0.90
Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol (2004) 0.88
Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation. Oncogene (2002) 0.82
Hepatocyte growth factor inhibits cell proliferation in vivo of rat hepatocellular carcinomas induced by diethylnitrosamine. Carcinogenesis (1995) 0.81
The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis (2006) 0.81
Hepatocyte growth factor enhancement of preneoplastic hepatic foci development in rats treated with diethylnitrosamine and N-ethyl-N-hydroxyethylnitrosamine. Jpn J Cancer Res (1995) 0.80
Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol (1994) 0.78
Hepatocyte growth factor stimulates DNA synthesis in rat preneoplastic hepatocytes but not in liver carcinoma cells. Gastroenterology (1998) 0.77
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Mosaic analysis with double markers in mice. Cell (2005) 5.32
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron (2003) 3.76
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol (2007) 2.33
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Systemic therapy for biliary tract cancers. Oncologist (2008) 1.98
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology (2007) 1.87
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology (2009) 1.63
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol (2012) 1.33
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg (2005) 1.30
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther (2009) 1.26
Gemcitabine-associated thrombotic microangiopathy. Cancer (2004) 1.26
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer (2011) 1.20
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci (2007) 1.15
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist (2009) 1.14
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (2015) 1.11
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg (2014) 1.11
Cholangiocarcinoma: current and novel imaging techniques. Radiographics (2008) 1.09
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.09
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist (2009) 1.09
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol (2013) 1.05
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One (2012) 1.05
Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol (2012) 1.03
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl (2004) 1.02
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res (2008) 1.01
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist (2011) 0.98
Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer (2014) 0.98
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol (2013) 0.97
Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery (2013) 0.96
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups. N Engl J Med (2005) 0.96
Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol (2007) 0.95
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer (2006) 0.95
Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw (2014) 0.93
Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci (2012) 0.92
Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol (2013) 0.92
A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist (2011) 0.91
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs (2009) 0.89
Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions. Radiology (2014) 0.88
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol (2009) 0.87
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.85
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer (2013) 0.84
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res (2011) 0.84
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett (2006) 0.84
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology (2012) 0.83
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist (2013) 0.83
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer (2014) 0.83
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res (2003) 0.82
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2007) 0.81
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.81
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.80
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci (2014) 0.80
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation. JAMA (2008) 0.80
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer (2012) 0.80
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward? J Clin Oncol (2012) 0.80
Microsatellite instability in gallbladder carcinoma. Virchows Arch (2015) 0.80
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol (2010) 0.79
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol (2015) 0.79
Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. J Vasc Interv Radiol (2013) 0.78
IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Rev Anticancer Ther (2012) 0.78
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys (2012) 0.77
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2013) 0.77
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer (2009) 0.77
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR Am J Roentgenol (2015) 0.77
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology (2005) 0.76
Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma? Cancer (2003) 0.75
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) (2010) 0.75
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol (2015) 0.75
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol (2017) 0.75
Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2015) 0.75
Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells? Am J Clin Oncol (2015) 0.75
Successful targeted therapies for hepatocellular carcinoma: are we really getting there? Expert Rev Anticancer Ther (2008) 0.75
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep (2017) 0.75
Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival. J Comput Assist Tomogr (2015) 0.75
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.75